Temozolomide (brand name Temodar®) is an oral alkylating agent used for the treatment of refractory anaplastic astrocytoma -- a type of cancerous brain tumour. A derivative of imidazotetrazine, temozolomide is the prodrug of MTIC (3-methyl-(triazen-1-yl)imidazole-4-carboxamide). Temodar is marketed by Schering Corporation, which also markets other well-known prescription drugs such as Clarinex, Nasonex, Levitra, Cipro, Vytorin, Diprolene, Elocon and Lotrisone.

Indications

Glioblastoma multiforme: for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as manitenance treatment.
Anaplastic astrocytoma: for the treatment of adult patients with refractory anaplastic atrocytoma (ie. patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine).
Unlabeled uses: Metastatic melanoma.

Dosage Forms

Temozolomide is available in the United States in 5mg, 20mg, 100mg, & 250mg capsules.

Read more at Wikipedia.org

• [List your site here Free!]

Brain cancer drug receives FDA approval
From Deseret News (Salt Lake City), 3/17/05

WASHINGTON (AP) -- The Food and Drug Administration on Wednesday approved use of the drug temozolomide for patients with the most common form of malignant brain cancer.

The agency said the drug, sold by Schering-Plough Corp. under the name Temodar, extended the life of patients who used the medication and had radiation therapy.

Patients with glioblastoma multiforme lived an average of 14.6 months while being treated Temodar and radiation, compared with 12.1 months for those receiving only radiation, the FDA said.

Return to Temodar

Home

Contact

Resources

Exchange Links

ebay